Fuzionaire Diagnostics Inc. has changed its name to Fuzionaire Theranostics Inc. to better reflect the company’s pipeline of paired fluorine-18 PET diagnostics and radioligand therapies to find and treat cancer.
Researchers from Delta-Fly Pharma Inc. presented preclinical data for DFP-14927, a polyethylene glycol (PEG)-conjugate of a deoxycytidine analogue, being developed as a potential anticancer agent.
Researchers from Zhejiang University of Technology presented the discovery of novel small compound candidates, designed with the aim of overcoming P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).
Critically shortened telomeres are a key limiting factor in successful CAR T-cell immunotherapy, with cells from older patients tending to have shorter telomeres with reduced dividing capacity. As such, these cells are unable to fully eliminate malignancies and provide durable and persistent protection against cancer.
The notion of taking aim at the galectin pathway across varied therapeutic areas has gained major traction in recent years, with a handful of companies drawing Wall Street’s interest as efforts plow forth in conditions as varied as cancer, liver fibrosis and Alzheimer’s disease.
Citius Pharmaceuticals Inc.’s retooled version of withdrawn cancer drug Ontak (denileukin diftitox) is not quite ready for prime time, according to the U.S. FDA, which issued a complete response letter (CRL) for the interleukin-2-diphtheria toxin fusion protein known as Lymphir. The agency is asking for Citius to incorporate enhanced product testing and additional controls but did not raise any concerns regarding safety and efficacy, the company said.
Research at Korea Research Institute of Chemical Technology (KRICT) has led to the identification of pyrazolopyrimidine-containing compounds acting as dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors and reported to be useful for the treatment of cancer.
858 Therapeutics Inc. has patented a series of 6,6-fused heterocyclic compounds acting as N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
Researchers from OSE Immunotherapeutics SA have published preclinical data for the novel anti-ChemR23 monoclonal antibody (MAb) (OSE-230) with anti-inflammatory properties, being evaluated for the potential treatment of cancer.
The non-receptor tyrosine kinase (TK) Src is the first oncogene ever identified. In tumors, Src hyperactivation is usually linked to the aberrant activation of upstream receptor tyrosine kinases (RTKs). In previous work, researchers from IRCCS-Fondazione Santa Lucia and collaborators developed a library of pyrazolo[3,4-d]pyrimidines inhibiting Src and other cytoplasmic TKs. Several compounds showed in vitro and in vivo activity in tumor models characterized by a deregulation of those kinases, such as osteosarcoma, neuroblastoma and glioblastoma.
RSS
